Last reviewed · How we verify
Pandemic Influenza Vaccine
A live attenuated intranasal vaccine that stimulates mucosal and systemic immune responses against pandemic influenza strains.
A live attenuated intranasal vaccine that stimulates mucosal and systemic immune responses against pandemic influenza strains. Used for Pandemic influenza prevention.
At a glance
| Generic name | Pandemic Influenza Vaccine |
|---|---|
| Sponsor | Altimmune, Inc. |
| Drug class | Live attenuated influenza vaccine (LAIV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine is administered intranasally and contains live attenuated influenza virus designed to replicate in the nasal mucosa, triggering both local mucosal immunity (IgA) and systemic immune responses (IgG and T-cell mediated immunity). This approach aims to provide broader and more durable protection compared to inactivated vaccines, particularly against pandemic influenza variants.
Approved indications
- Pandemic influenza prevention
Common side effects
- Nasal congestion
- Runny nose
- Sore throat
- Cough
- Fever
Key clinical trials
- A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults (PHASE3)
- Vaccine Pandemic Preparedness Through Airway Immunology Characterization (EARLY_PHASE1)
- A Phase I/II Study on Safety AND Immunogenicity of AZD4117 and AZD5315 Vaccines (PANDA) (PHASE1, PHASE2)
- A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza (PHASE1)
- Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients (PHASE2)
- A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults (PHASE1, PHASE2)
- Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults (PHASE1)
- Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pandemic Influenza Vaccine CI brief — competitive landscape report
- Pandemic Influenza Vaccine updates RSS · CI watch RSS
- Altimmune, Inc. portfolio CI